The cover image of "Non-Sinus-Type Dural Arteriovenous Fistula at the Foramen Magnum: A Review of the Literature", 2025 Volume 19 Issue 1 Article ID: ra.2023-0019.
dAVFs can be divided into two groups, “sinus type” and “non-sinus type”. Non-sinus type involves the anterior cranial fossa, tentorial, sphenoid wing, foramen magnum, convexity, parasagittal, and falcine dAVFs. In recent years, with improvements in imaging quality and embolic materials and catheters, endovascular treatment for these non-sinus type dAVFs has been increasing. However, non-sinus type locations were risk factor for complications of dAVFs embolization. This special issue describes clinical characteristics and treatment strategy for those non-sinus type dAVFs.
The cover image of "Transvenous Embolization for Brain Arteriovenous Malformations", 2025 Volume 19 Issue 1 Article ID: ra.2024-0035.
This special feature on arteriovenous malformation (AVM) is structured into four sections: Basic knowledge and overview, pathogenesis and therapeutic targets, transarterial embolization, transvenous embolization, and types of AVM including unclassified AV shunts. It offers a systematic and comprehensive approach to learning about AVMs, covering everything from basic concepts to the latest developments in the field. We hope these findings will be helpful in your daily clinical practice.
The cover image of "N-butyl Cyanoacrylate Use in Various Neuroendovascular Diseases", 2025 Volume 19 Issue 1 Article ID: ra.2024-0062.
The history of embolic material development is essentially that of neuroendovascular treatment. In the early days of AVM embolization, the only catheter capable of being guided near the AVM was the calibrated leak balloon, and the only embolic material that could be injected from it was IBCA (a substance similar to NBCA). Younger readers should also be aware that ONYX, now the mainstream liquid embolic material, is actually a copy of EVAL or CAP, developed in Japan in the 1980s. The emergence of retrievable coils (GDC) in the 1990s made detachable coils the mainstream material for safe neurovascular embolization. However, the needs of liquid embolic materials remain very high for conditions such as shunt disease and vascular injuries requiring emergency hemostasis. We sincerely hope this special feature provides readers with valuable information while also enhancing their skills in using liquid embolic materials.
The cover image of "Artificial Intelligence in Neuroendovascular Procedures", 2025 Volume 19 Issue 1 Article ID: ra.2024-0107.
This special issue titled "For further development in neuroendovascular therapy" comprises five six articles: two focusing on artificial intelligence (AI), one on robotics, one on telemedicine, one addressing the qualification examination of JSNET, and one discussing the mission and future direction of WFITN. This collection serves as a valuable resource offering insights into the future landscape of neuroendovascular therapy.
The cover image of "Antithrombotic Therapy for Acute Coronary Syndrome", 2025 Volume 19 Issue 1 Article ID: ra.2024-0102.
Antithrombotic therapy is essential in many endovascular procedures to prevent perioperative thromboembolic complications. Accordingly, a comprehensive understanding of perioperative antithrombotic management is crucial for us. This special issue comprises five articles addressing various aspects of antithrombotic therapy in endovascular procedures, encompassing a wide range of interventions from cardiovascular diseases to the endovascular treatment of cerebral aneurysms. We hope that this special issue will be useful to readers and contribute to improved perioperative management in clinical practice.
The cover image of "Anatomy of the Middle Meningeal Artery: Implications for Middle Meningeal Artery Embolization in Chronic Subdural Hematoma", 2026 Volume 20 Issue 1 Article ID: ra.2025-0131.
Middle meningeal artery (MMA) embolization is an emerging minimally invasive treatment for chronic subdural hematoma (CSDH), with increasing evidence supporting its efficacy in reducing recurrence and promoting hematoma resolution. Recent data, including nationwide experience in Japan, demonstrate its safety and expanding clinical use.
This special issue summarizes current evidence, real-world outcomes, and technical advances of MMA embolization, highlighting its evolving role and potential as a standard treatment option for CSDH.